They also found that RA patients with high baseline ADAMTS5 mRNA levels did not improve following IFX treatment, implying that IFX is unable to prevent aggrecan degradation by ADAMTS5 (55). This evidence concerns the gene ADAMTS5 and rheumatoid arthritis.